Lainate, December 2012
R&D Investor day at Cosmo Pharmaceuticals, 25 January 2013
Dear Madam or Sir,
In 2012 Cosmo substantially progressed in the development of its portfolio. As
things stand decisions on the regulatory approval of Cortiment/Uceris are
imminent and phase III data for Rifamycin SV MMX and Methylene Blue MMX should
be available in H2 2013.
Cosmo is pleased to invite you to an R&D day held at the company's premises in
Milano-Lainate. Management will give insight to its shareholders, analysts and
the press into the next steps on Cortiment/Uceris, the development plans of
Rifamycin SV MMX, Methylene Blue MMX, and CB 03-01, the topical anti androgen
for the treatment of acne and alopecia. Senior Management including Chairman
and CEO Mauro Ajani, CSO Dr. Luigi Moro as well as Prof A. Repici of Humanitas
Hospital in Milano will be presenting and available throughout the day.
The meeting will take place on 25 January 2013, starting at 11:00am. It will
last through 4:00pm with a buffet lunch and opportunities of talking to key
Cosmo people throughout the day. For participants traveling from Zurich, pick
up will be arranged at Como San Giovanni at 10:15am and they will be brought
back to Como San Giovanni after the meeting.
We look forward to welcoming you in Lainate and ask you to kindly confirm your
participation by 10 January 2013, replying via e-mail or using the form
Chief Financial Officer
Registration Form (PDF)
Provider Channel Contact
Tensid Ltd., Switzerland newsbox.ch Provider/Channel related enquiries
www.tensid.ch www.newsbox.ch firstname.lastname@example.org
+41 41 763 00 50
Press spacebar to pause and continue. Press esc to stop.